Date: 2012-11-09
Type of information: R&D agreement
Compound: novel classes of small molecules against certain biological targets
Company: GSK (UK) Chiromics (USA)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Chiromics has announced a collaboration with GSK to discover novel classes of small molecules against certain biological targets. Chiromics is a drug discovery company that designs and synthesizes broadly diverse chemical compound libraries, using a patented “cascade catalysis” technology that produces drug-like molecules with a stereochemically defined framework. The novel structures and accessible complexity of these compounds expands the access to important disease targets and accelerates the hit-to-lead time for identification of novel drugs.
Financial terms:
Latest news:
